Antiretroviral therapy in HIV-infected pregnant women and their infants: Current interventions and challenges

Journal of Perinatal and Neonatal Nursing

Volumn 16, Issue 2, 2002, Pages 1-25

  Shannon, Maureen ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretroviral therapy; HIV; Pregnancy

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

DISEASE TRANSMISSION; FEMALE; HEALTH SERVICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; ISOLATION AND PURIFICATION; NEWBORN; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY COMPLICATION; REVIEW; STANDARD; UNITED STATES; WOMEN'S HEALTH;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; MATERNAL HEALTH SERVICES; PRACTICE GUIDELINES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REVERSE TRANSCRIPTASE INHIBITORS; UNITED STATES; WOMEN'S HEALTH;

EID: 0036717937     PISSN: 08932190     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005237-200209000-00003     Document Type: Article

References (68)

1. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. Midyear Edition. 2002;13:1-41.
2. Joint United Nations Programme on HIV/ AIDS. AIDS Epidemic Update. Geneva, Switzerland: UNAIDS; 2001.
3. Scott GB, Tuomala R. Combination antiretroviral therapy during pregnancy. AIDS. 1998;12:2495-2497.
4. Minkoff H, Ahdieh L, Watts H, et al. The relationship of pregnancy to the use of highly active antiretroviral therapy. Am J Obstet Gynecol. 2001;184:1221-1227.
5. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173-1180.
6. Rutstein RM. Prevention of perinatal HIV infection. Curr Opin Pediatr. 2001;13:408-416.
7. Ioannidis JPA, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/mL. J Infect Dis. 2000;183:539-545.
8. Shapiro D, Tuomala R, Samelson R, et al. Mother-to-child HIV transmission rates according to antiretroviral therapy, mode of delivery, and viral load (PACTG 367). In: 9th Conference on Retroviruses and Opportunistic Infections (February 2002). http:// www.retroconference.org/2002/abstracts/ default.htm. Accessed March 4, 2002.
9. Brocklehurst P, Volmink J. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection (Cochrane Review). The Cochrane Library, Oxford: Update Software; 2002.
10. Bucceri AM, Somigliana E, Matrone R, et al. Combination antiretroviral therapy in 100 HIV-1 infected pregnant women. Hum Reprod. 2002;17:436-441.
11. Cooper ER, Charurat M, Burns DN, Blattner W, Hoff R, The Women and Infants Transmission Study Group. Trends in antiretroviral therapy and mother-infant transmission of HIV. J Acquired Immune Defic Syndrome. 2000;24:45-47.
12. European Collaborative Study. HIV-infected pregnant women and vertical transmission in Europe since 1986. AIDS. 2001;15:761-770.
13. Patel J, Melville S, Heath C, et al. Role of combination antiretroviral therapy and mode of delivery in perinatal HIV transmission (PHT), Pediatric Spectrum of Disease Project (PSD), United States, 1995-2000. In: 9th Conference on Retroviruses and Opportunistic Infections (February 2002). http :// www . retroconference . org/2002/ abstracts/default.htm. Accessed March 4, 2002.
14. Casey CM, Cohen F, Hughes A. ANAC's Core Curriculum for HIV/AIDS Nursing. Philadelphia: Nursecom; 1996.
15. Ho D, Neumann AU, Perelson AS, Chen W, Leonard JM. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-126.
16. Bartlett JG, Gallant JE. 2001-2002 Medical Management of HIV Infection. Baltimore, MD: Johns Hopkins University, Division of Infectious Diseases; 2001.
17. Public Health Service Task Force. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents (February 4, 2002). http://www.hivatis.org. Accessed February 6, 2002.
18. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD44+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;128:946-954.
19. Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med. 2001:344:720-725.
20. Gandhi M, Bacchetti P, Miotti P, Quinn T, Veronese F, Greenblatt R. Effect of gender/sex on viral load, pharmacokinetics and responses to antiretroviral therapy. In: 9th Conference on Retroviruses and Opportunistic Infections (February 2002). http:// www .retroconference.org/2002/abstracts/ default.htm. Accessed March 5, 2002.
21. Kauf TL, Gibbons DC, Kirkland TL, Capuano G, Tolson JM, Goodwin D. Modeling the impact of revised DHHS HIV treatment guidelines on survival in women. Abstract presented at 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago, IL.
22. Kessler H, Deeks SG, Grant RM. Understanding Assays - Guide to HIV Resistance Tests. Atlanta, GA: Meditech Media Inc; 2000.
23. Project Inform. Drug Interactions. San Francisco: Project Inform; 2001.
24. Folch E, Hernandez I, Vetter T, Browning J, del Rio C, Lennox J. Predictors and causes of mortality in HIV disease. In: 9th Conference on Retroviruses and Opportunistic Infections (February 2002). http:// www.retroconference.org/2002/abstracts/ default.htm. Accessed March 6, 2002.
25. Hogg R, Yip B, Chan K, et al. Changes in both CD4 cell counts and HIV-1 RNA levels predict subsequent disease progression among HIV-1 infected persons initiating antiretroviral therapy. In: 9th Conference on Retroviruses and Opportunistic Infections (February 2002). http:// www.retroconference.org/2002/abstracts/ default.htm. Accessed March 5, 2002.
26. Rodriguez B, Valdez H, Salata R, et al. Changes in the causes of death in a cohort of HIV-infected individuals: analysis of the last 6 years. In: 9th Conference on Retroviruses and Opportunistic Infections (February 2002). http://www.retroconference.org/2002/abstracts/default.htm. Accessed March 5, 2002.
27. Hare CB, Peters MG, Watson JJ, Mark DG, Jacobson MA. Hepatitis viruses: influence on morbidity, mortality, and response to antiretroviral therapy. In: 9th Conference on Retroviruses and Opportunistic Infections (February 2002). http://www. retroconference.org/2002/abstracts/default. htm. Accessed March 5, 2002.
28. Hoffman-Terry ML, O'Donnell E. Wasylik A, Wasser T, Saqib MN. Factors associated with hyperglycemia complicating HAART in the HIV/HCV coinfected population. Presented at 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago, IL.
29. Marcus K, Truffa M, Boxwell C, Toerner J. Recently identified adverse events secondary to NRTI therapy in HIV-infected individuals: cases from the FDA's adverse event reporting system (AERS). In: 9th Conference on Retroviruses and Opportunistic Infections (February 2002). http://www. retroconference.org/2002/abstracts/default. htm. Accessed March 5, 2002.
30. Moore RD, Keruly JC, Chaisson RE. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. AIDS. 2001;15: 617-620.
31. Frederiksen MC. Physiologic changes in pregnancy and their effect on drug disposition. Semin Perinatol. 2001;25:120-123.
32. Public Health Service Task Force. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1 Infected Women for Maternal Health and Interventions To Reduce Perinatal HIV-1 Transmission in the United States (February 4, 2002). http:// www.hivatis.org. Accessed February 6, 2002.
33. Rodman JH. Design of antiretroviral clinical trials for HIV-1 infected pregnant women and their newborn infants. Semin Perinatol. 2001;25:170-176.
34. Gilstrap LC. Effects of pregnancy on specific diseases. Semin Perinatol. 2001;25: 139-144.
35. Mandelbrot L, Landreau-Mascaro C, Rekacewicz C, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA. 2001;285:2083-2093.
36. Hill JB, Sheffield JS, Zeeman GG, Wendel GD Jr. Hepatotoxicity with antiretroviral treatment of pregnant women. Obstet Gynecol. 2001;98:909-911.
37. Philip AGS. Neonatology: A Practical Guide. Philadelphia: W.B. Saunders; 1996.
38. Mirochnick M. Antiretroviral pharamacology in pregnant women and their newborns. Ann NY Acad Sci. 2001;918:287-297.
39. Mirochnick M, Dorenbaum A, Blanchard S, et al. Pre-dose infant nevirapine (NVP) concentration with the 2-dose intrapartum (IP)-infant NVP regimen. In: 9th Conference on Retroviruses and Opportunistic Infections (February 2002). http:// www.retroconference.org/2002/abstracts/ default.htm. Accessed March 5, 2002.
40. Bryson Y, Stek A, Mirochnick M, et al. Pharmacokinetics, antiviral activity, and safety of nelfinavir (NFV) with ZDV/3TC in pregnant HIV-infected women and their infants: PACTG 353 Cohort 2 (February 2002). http://www.retroconference.org/2002/abstracts/default.htm. Accessed March 4, 2002.
41. McGhee K, Shields K, Benson J, Beninger P, Sharrar R. 5-year review of maternal-fetal outcomes in patients exposed to indinavir sulfate during pregnancy. In: 9th Conference on Retroviruses and Opportunistic Infections (February 2002). http:// www.retroconference.org/2002/abstracts/ default.htm. Accessed March 5, 2002.
42. Mirochnick M, Dorenbaum A, Cunningham-Schrader B, et al. Cord blood protease inhibitor (PI) concentrations in infants born to mothers receiving PI's. In: 8th Conference on Retroviruses and Opportunistic Infections (February 2001). http:// www.retroconference.org/2001/abstracts/ default.htm. Accessed March 1, 2002.
43. Scott G, Rodman J, Scott W, et al. Pharmacokinetic and virologic response to ritonavir (RTV) in combination with zidovudine (ZDV) and lamivudine (3TC) in HIV-1 infected pregnant women and their infants. In: 9th Conference on Retroviruses and Opportunistic Infections (February 2002). http://www.retroconference.org/2002/ abstracts/default.htm. Accessed March 1, 2002.
44. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 July 2001. Wilmington, NC: Registry Project Office; 2001.
45. Garcia PM, Beckerman K, Watts H, et al. Assessing the teratogenic potential of antiretroviral drugs: data from the Antiretroviral Pregnancy Registry (APR). Presented at 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago, IL.
46. Fundaro C, Genovese O, Rendeli C, Tamburrini E, Salvaggio E. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS. 2002;16:299-300.
47. Culnane M, Fowler M, Lee SS, et al. Lack of long-term effects of in-utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA. 1999;281:151-157.
48. Capparelli E, Mirochnick M, Dankner W, et al. Population pharmacokinetics of zidovudine in premature HIV-exposed infants. Presented at Pediatric Academic Societies and American Academy of Pediatrics Joint Meeting; May 15, 2000; Boston, MA.
49. Fernandez AD, McNeeley DF. Management of the infant born to a mother infected with human immunodeficiency virus type 1 (HIV-1): current concepts. Am J Perinatol. 2000;17:429-436.
50. Lallemant M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;343:982-991.
51. Blanche S, Tarkieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 1999;354:1084-1089.
52. Lindegren ML, Rhodes P, Gordon L, Fleming P. Drug safety during pregnancy and in infants: lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance. Ann NY Acad Sci. 2000;918:222-233.
53. Alimenti A, Ogilvie G, Burdge D, Money D, Forbes J. Lactic academia in infants exposed to perinatal antiretroviral therapy. In: 9th Conference on Retroviruses and Opportunistic Infections (February 2002). http://www.retroconference.org/2002/ abstracts/default.htm. Accessed March 6, 2002.
54. Giaquinto C, De Romeo A, Giacomet V, et al. Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission. AIDS. 2001; 15:1074-1075.
55. Dorenbaum A, The PACTG 316 Study Team. Report of results of PACTG 316: an international phase III trial of standard antiretroviral (ARV) prophylaxis plus nevirapine (NVP) for prevention of perinatal HIV transmission. In: 8th Conference on Retroviruses and Opportunistic Infections (February 2001). http:// www.retroconference.org/2001/abstracts/ default.htm. Accessed March 1, 2002.
56. R) mutations in Ugandan women and infants receiving NVP prophylaxis to prevent HIV-1 vertical transmission (HIVNET 012). In: 8th Conference on Retroviruses and Opportunistic Infections (February 2001). http://www.retroconference.org/2001/abstracts/default.htm. Accessed February 1, 2002.
57. Fowler MG, Mwatha A, Guay L, et al. Effect of nevirapine (NVP) for perinatal HIV prevention appears greatest among women with most advanced diseases: subgroup analyses of HIVNET 012. In: 9th Conference on Retroviruses and Opportunistic Infections (February 2002). http:// www.retroconference.org/2002/abstracts/ default.htm. Accessed March 5, 2002.
58. Cunningham CK, Britto JP, Gelber R, et al. Genotypic resistance analysis in women participating in PACTG 316 with HIV-RNA >400 copies/mL. In: 8th Conference on Retroviruses and Opportunistic Infections (February 2001). http://www. retroconference.org/2001/abstracts/default. htm. Accessed March 1, 2002.
59. The European Collaborative Study and the Swiss Mother & Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS. 2000;14: 2913-2920.
60. Lambert JS, Watts DH, Mofenson L, et al. Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine. AIDS. 2000;14:1389-1399.
61. Orloff SL, Bulterys M, Vink P, et al. Maternal characteristics associated with antenatal, intrapartum, and neonatal zidovudine use in four US cities, 1994-1998. J Acquired Immune Defic Syndrome. 2001; 28:65-72.
62. Patchen L, Khoshnood K. Risk of perinatal transmission with treatment combinations of intrapartum and newborn zidovudine monotherapy. AIDS Reader. 2001;11:274-275.
63. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med. 1998;339:1409-1414.
64. Laine C, Newshaffer CJ, Zhang D, Cosler L, Hauck WW, Turner BJ. Adherence to antiretroviral therapy by pregnant women infected with human immunodeficiency virus: a pharmacy claims-based analysis. Obstet Gynecol 2000;95:167-173.
65. Turner BJ, Newschaffer CJ, Zhang D, Cosler L, Hauck WW. Antiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women. Med Care. 2000;38:911-925.
66. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001;344: 520-522.
67. Casiday R, Frey R. Drug strategies to target HIV: enzyme kinetics and enzyme inhibitors. In: Chemical Kinetic Experiment (2001). http://wunmr.wustl.edu/EduDev/ LabTutorials/HIV/DrugStrategies.html. Accessed February 2, 2002.
68. Shannon MT, Ammann A, Petru A, Mirochnick M. ACTG protocol 076 AZT regimen to reduce mother to child transmission. In: Women, Children, and HIV: Resources for Prevention and Treatment [fact sheet on CD rom]. 2nd ed. San Francisco: Global Strategies for HIV Prevention and HIV InSite of the University of California; 2002.